01 May 2025
01 May 2025
Companies are developing myostatin inhibitors for GLP-1RA- related muscle loss, but some experts doubt their necessity.
GSK鈥檚 CEO Emma Walmsley said that the company is starting 鈥渇rom a position of strength鈥�.
The slowdown in IPOs following tariff-associated turbulence and FDA reorganisation will soon pass, say industry investors.
Data from the NERO study was presented at the American Association of Cancer Research (AACR) Annual Meeting 2025.
The approval by the US regulator is based on data from the pivotal Vivacity-MG3 trial.
Total consideration for the acquisition, including the CVR, could reach $1.7bn.
Signs of a recovery in biopharmaceutical venture financing emerged in 2024, characterised by an increase in total deal value and larger funding rounds.
The NeuLogiq neuroassessment platform from Cumulus will be leveraged in the BPD patient population.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
